Research
Hormonal
Incretin hormone agonists offer substantial weight reduction and cardiometabolic benefits.
Practitioners can consider incretin hormone agonists as effective options for obesity management.
StrongSupportsmedium confidence
Incretin hormone agonists represent a significant advancement in the pharmacotherapy of obesity, offering substantial weight reduction and cardiometabolic benefits.
Why this rating
Supported by key clinical trials mentioned in the abstract.
Source
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Ibrahim S. Alhomoud et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
reviewCited 19×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →